UPDATE 1-EU clears shorter course of Roche hepatitis C drug

Written by Linda

Saturday, 28 June 2008 00:22

URICH, June 26 (Reuters) - Roche Holding AG (ROG.VX: Quote, Profile, Research) said on Thursday it had received European Union approval for a shortened treatment course for Pegasys in combination with Copegus for certain hepatitis C patients.

The 16-week course will be available for patients with genotype 2 or 3 strains of chronic hepatitis C who have low virus levels before starting treatment and show rapid virological response, the Basel-based drug maker said.

The altered course of treatments is part of Roche's new response-guided therapy, which seeks to customise regimens based on how well patients respond to therapy.

Roche also announced the start of NCORE study to determine the best treatment time for patients who do not experience a rapid response.

(Reporting by Andrew Thompson; Editing by Erica Billingham)

http://uk.reuters.com

Set as favorite

Bookmark

Email This

Comments (0) add comment

Subscribe to this comment's feed

Write comment

Title
Comment	smaller \| bigger
Name
Email
Website
Write the displayed characters
I have read and agree to the Terms of Usage.

Site, Article & Information Disclaimer

All information and articles provided on our website and forums are to be used as a guideline only. For your own safety, please always consult with a doctor or specialist before making any decisions regarding your health care. By visiting this website you instantly adhere to this policy.